AZD5148
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridioides Difficile Infection
Conditions
Clostridioides Difficile Infection
Trial Timeline
Dec 10, 2025 → Jan 18, 2028
NCT ID
NCT07285213About AZD5148
AZD5148 is a phase 2 stage product being developed by AstraZeneca for Clostridioides Difficile Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07285213. Target conditions include Clostridioides Difficile Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07285213 | Phase 2 | Recruiting |
Competing Products
7 competing products in Clostridioides Difficile Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD5148 + Placebo | AstraZeneca | Phase 1 | 33 |
| C.difficile vaccine | Pfizer | Phase 3 | 76 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| REC-3964 | Recursion Pharmaceuticals | Phase 2 | 47 |
| SER-109 | Seres Therapeutics | Pre-clinical | 15 |
| SER-109 | Seres Therapeutics | Phase 3 | 69 |